Jeremy Grantham Jounce Therapeutics, Inc. Transaction History

Grantham, Mayo, Van Otterloo & Co. LLC

  • $29.8 Billion
  • Q4 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Aug 13, 2020
SELL
$4.17 - $7.58 $43,368 - $78,832
-10,400 Closed
0 $0
Q1 2020

May 14, 2020
BUY
$2.91 - $8.7 $30,264 - $90,479
10,400 New
10,400 $49,000

Others Institutions Holding JNCE

# of Institutions
4
Shares Held
720K
Call Options Held
0
Put Options Held
0
View Full List

About Jounce Therapeutics, Inc.

JNCE Quotes by TradingView
  • Ticker JNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,694,200
  • Description
  • Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...
More about JNCE
Track Jeremy Grantham's Portfolio

Track Jeremy Grantham Portfolio

Follow Jeremy Grantham (Grantham, Mayo, Van Otterloo & Co. LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Grantham, Mayo, Van Otterloo & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Grantham, Mayo, Van Otterloo & Co. LLC and Jeremy Grantham with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email